https://www.selleckchem.com/pr....oducts/hydroxychloro
The most often used initial omalizumab dose was 300 mg every 4 weeks (n=16). Most patients ultimately achieved clinical response after starting omalizumab complete response (63%, n=22), partial response (28.5%, n=1, with 3 nonresponders. Omalizumab may be an effective treatment option for patients with IA who do not have evidence of mast cell clonality and fail to respond to antihistamines and mast cell stabilizers. Omalizumab may be an effective treatment option for patients with IA who do not have evidence of mast
Me gusta
Comentario
Compartir
